|
|
|
| Brand | Other Names | Presentation | Strengths | Enquire |
| Salofalk ® | mesalazine, 5-ASA | Enema | 4 g/60 mL x 7 | |
| Enema | 2 g/60 mL x 7 | |||
| Tablets | 500 mg x 100 tablets | |||
| Granules | 500 mg x 100 sachets | |||
| Granules | 1.5 g x 60 sachets | |||
| Granules | 1 g x 100 sachets | |||
| Foam enema | 1 g/application; sufficient for 14 applications | |||
| Suppositories | 1 g x 30 suppositories |
| TGA indication | |
SALOFALK tablets are indicated in the treatment of acute episodes and maintenance of remission of: i. Mild to moderate ulcerative colitis and; | |
SALOFALK granules are indicated in the treatment of acute ulcerative colitis of mild to moderate severity and for the maintenance of remission and/or the long term treatment of ulcerative colitis. | |
SALOFALK foam enemas are indicated in the treatment of acute ulcerative colitis of mild to moderate severity and for the maintenance treatment of ulcerative colitis | |
SALOFALK enemas are indicated in the treatment of acute ulcerative colitis of mild to moderate severity and for the maintenance treatment of ulcerative colitis. | |
| SALOFALK suppositories are indicated in the treatment of ulcerative proctitis. | |
| PBS listing | |
TABLETS (500mg) : Authority required (STREAMLINED)
| |
GRANULES (500mg, 1g, 1.5g) : Authority required (STREAMLINED)
Note: Not for the treatment of Crohn's disease. | |
ENEMAS (2g in 60 ml, 4g in 60ml) and FOAM ENEMAS (14 applications/can) : Authority required (STREAMLINED)
| |
| Information for Patients | |
| Consumer Medicine Information (oral) | |
| Consumer Medicine Information (rectal) |
|
| Information for Healthcare Professionals | |
| Product Information (oral) | |
| Product Information (rectal) |
|
